Phase 1 Neuropathy Clinical Trials
11 recruitingPhase 1
What is a Phase 1 trial?
Phase 1 trials test a new treatment in a small group of people for the first time. The primary goal is to evaluate safety, determine a safe dosage range, and identify side effects. These studies typically enroll 20 to 80 participants.
Showing 1–11 of 11 trials
Recruiting
Phase 1
Intraneural Administration of scAAV9/JeT-GAN Into the Vagus Nerve for Patients With Giant Axonal Neuropathy (GAN)
Giant Axonal Neuropathy (GAN)
University of Texas Southwestern Medical Center4 enrolled1 locationNCT07543991
Recruiting
Phase 1
A Study Evaluating the Safety and Efficacy of KITE-363 in Relapsed/Refractory Autoimmune Neurologic Diseases
Myasthenia GravisMultiple SclerosisChronic Inflammatory Demyelinating Polyneuropathy
Kite, A Gilead Company52 enrolled3 locationsNCT07304154
Recruiting
Phase 1
Safety and Pharmacodynamics of QH103 Cell Injection in the Treatment of Patients With Relapsed/Refractory Antibody-Mediated Neurological Autoimmune Diseases.
Neuromyelitis Optica Spectrum Disorder (NMOSD)Multiple Sclerosis (MS)Myasthenia Gravis (MG)+3 more
Tongji Hospital6 enrolled1 locationNCT07526493
Recruiting
Phase 1Phase 2
A Basket Clinical Study to Assess Glycerol Tributyrate in Patients With Mitochondrial Encephalopathy, Lactic Acidosis, Stroke-like Episodes (MELAS) or Leber's Hereditary Optic Neuropathy-Plus (LHON-Plus)
MELAS SyndromeLebers Hereditory Optic Neuropathy With Extra Ocular Symptoms (LHON-Plus)
George Washington University24 enrolled1 locationNCT06792500
Recruiting
Phase 1
IVIG vs SCIG in CIDP
Chronic Inflammatory Demyelinating PolyneuropathyCIDPImmunoglobulin Deficiency
Rutgers, The State University of New Jersey20 enrolled1 locationNCT05584631
Not Yet Recruiting
Phase 1
A Phase 1 Open-label, Multiregional, Multicenter, Basket Study Evaluating the Safety and Efficacy of KITE-363, an Autologous Anti-CD19/CD20 CAR T-cell Therapy in Participants with Relapsed/Refractory Autoimmune Neurologic Diseases
Myasthenia GravisMultiple SclerosisChronic Inflammatory Demyelinating Polyneuropathy
Kite, A Gilead Company52 enrolled2 locationsACTRN12625001346460
Recruiting
Phase 1Phase 2
Safety and Efficacy of BAFF-R CART for Refractory Neuroimmune Diseases
Myasthenia GravisNMO Spectrum DisorderChronic Inflammatory Demyelinating Polyradiculoneuropathy+1 more
Tianjin Medical University General Hospital27 enrolled1 locationNCT07022197
Recruiting
Phase 1
Safety of Cultured Allogeneic Adult Umbilical Cord Stem Cells Exosomes for Trigeminal Neuralgia
Peripheral NeuropathyTrigeminal Neuralgia
The Foundation for Orthopaedics and Regenerative Medicine20 enrolled1 locationNCT05152368
Recruiting
Phase 1
Safety of Cultured Allogeneic Adult Umbilical Cord Derived Mesenchymal Stem Cells for NAION
Retinitis PigmentosaMacular DegenerationDiabetic Retinopathy+3 more
The Foundation for Orthopaedics and Regenerative Medicine20 enrolled2 locationsNCT05147701
Recruiting
Phase 1Phase 2
A Phase I/IIa，Open-label, Single Ascending Dose and Dose-expansion Clinical Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of YOLT-201 in Patients With Transthyretin Amyloidosis Polyneuropathy (ATTR-PN) or Transthyretin Amyloidosis Cardiomyopathy (ATTR-CM)
Transthyretin Amyloidosis PolyneuropathyTransthyrexin Amyloidosis Cardiomyopathy
YolTech Therapeutics Co., Ltd31 enrolled3 locationsNCT06539208
Not Yet Recruiting
Phase 1
A Randomized, Double-Blind, Placebo-Controlled, Multiple Dose, Safety, Tolerability and Pharmacokinetic Study of Topical Pirenzepine in Healthy Volunteers
Diabetic Peripheral Neuropathy
WinSanTor Australia Pty Ltd24 enrolled1 locationACTRN12617000535370